Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

MabVax Therapeutics Holdings Inc (NASDAQ:MBVX)

3.07
Delayed Data
As of Feb 23
 +0.26 / +9.25%
Today’s Change
2.51
Today|||52-Week Range
6.48
-9.17%
Year-to-Date
No recent news for MabVax Therapeutics Holdings Inc.

Today’s Trading

Previous close2.81
Today’s open3.04
Day’s range2.86 - 3.57
Volume1,173,311
Average volume (3 months)69,534
Market cap$17.7M
Dividend yield--
Data as of 3:59pm ET, 02/23/2017

Growth & Valuation

Earnings growth (last year)+80.86%
Earnings growth (this year)--
Earnings growth (next 5 years)+54.00%
Revenue growth (last year)+303.29%
P/E ratioNM
Price/Sales10.73
Price/Book1.45

Competitors

 Today’s
change
Today’s
% change
MBRXMoleculin Biotech In...-0.08-7.08%
OGXIOncoGenex Pharmaceut...-0.04-6.51%
ONTXOnconova Therapeutic...-0.06-2.14%
SBOTStellar Biotechnolog...+0.01+0.32%
Data as of 3:38pm ET, 02/23/2017

Financials

Next reporting dateMarch 14, 2017
EPS forecast (this quarter)-$0.86
Annual revenue (last year)$1.3M
Annual profit (last year)-$18.1M
Net profit margin-1,428.95%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
John David Hansen
Chief Financial Officer
Gregory P. Hanson
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs